Literature DB >> 3460692

Decreased concentration of xanthine dehydrogenase (EC 1.1.1.204) in rat hepatomas.

T Ikegami, Y Natsumeda, G Weber.   

Abstract

Xanthine dehydrogenase (EC 1.1.1.204), the rate-limiting enzyme of purine degradation, was purified 642-fold to homogeneity from liver of male Wistar rats. Antibody was generated to the purified enzyme in white rabbits and was partially purified. For the immunotitration a radioassay of high sensitivity was developed to determine low enzyme activities. Titration curves with the antibody showed that the xanthine dehydrogenase enzyme protein amounts in slowly growing hepatoma 20 and rapidly growing hepatoma 3924A were 34 and 4% of those of normal liver, which was in good agreement with the decrease in the activity of the enzyme to 33 and 2%, respectively. The contents of flavin adenine dinucleotide, the essential cofactor of the enzyme, in the immunoprecipitates in hepatomas 20 and 3924A were 27 and 4% of that of the normal liver. This is the first report to provide immunological evidence that a decreased enzyme activity in rat hepatomas, that of xanthine dehydrogenase, was due to a decrease in the enzyme protein amount. The markedly decreased xanthine dehydrogenase activity and amount have far-reaching biochemical and pharmacological implications for the tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer.

Authors:  N Linder; C Haglund; M Lundin; S Nordling; A Ristimäki; A Kokkola; J Mrena; J-P Wiksten; J Lundin
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group.

Authors:  Ozgur Tanriverdi; Suna Cokmert; Esin Oktay; Kezban Nur Pilanci; Serkan Menekse; Muharrem Kocar; Cenk Ahmet Sen; Nilufer Avci; Tulay Akman; Cetin Ordu; Gamze Goksel; Nezih Meydan
Journal:  Med Oncol       Date:  2014-09-13       Impact factor: 3.064

Review 3.  Mechanistic insights into the treatment of iron-deficiency anemia and arthritis in humans with dietary molybdenum.

Authors:  Brian James Grech
Journal:  Eur J Clin Nutr       Date:  2021-01-29       Impact factor: 4.884

Review 4.  Xanthine oxidoreductase in cancer: more than a differentiation marker.

Authors:  Maria Giulia Battelli; Letizia Polito; Massimo Bortolotti; Andrea Bolognesi
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452

5.  Contribution of uric acid to cancer risk, recurrence, and mortality.

Authors:  Mehdi A Fini; Anthony Elias; Richard J Johnson; Richard M Wright
Journal:  Clin Transl Med       Date:  2012-08-15

6.  Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues.

Authors:  R F Anderson; K B Patel; K Reghebi; S A Hill
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.